Takeda Pharmaceutical Company Limited

Tomokazu Kusumoto

Shigekazu Sasaki

Hideyuki Sugiyama

Tatsuki Koike

Hidekazu Tokuhara

Shuhei Ikeda

Jumpei Aida

Makoto Fushimi

Hiroyuki Nagamiya

Yasushi Hattori

Hideo Suzuki

Masaki Seto

Tsuneo Oda

Makoto Kamata

Junya Shirai

Masato Yoshida

Hironobu Maezaki

Takahiro Matsumoto

Shogo Marui

Yuji Ishichi

Izumi Nomura

Hyun Bin Kang

Takatoshi Yogo

Hye Sun Jeon

Cheolhwan Yoon

Chul Yun Rhim

Kwang Ok Kim

Gil Nam Lee

Masako Miyazaki

The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification,or a salt thereof.

Heterocyclic compound

The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors

The present invention provides a compound having a superior serotonin 5-HTreceptor activating action. The present invention relates to a compound represented by the formula (1) wherein

Tricyclic compound

Provided is a compound having a serotonin 5-HTreceptor activating action, useful for lower urinary tract conditions, obesity and cancer. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Pyrazinooxazepine derivatives

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides a compound having a superior serotonin 5-HTreceptor activating action, which is represented by the formula wherein A is &#x2014;ORor &#x2014;S(O)R, Rand Rare the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group to optionally having substituent(s), and p is 0, 1 or 2, or a salt thereof.

Pyridooxazepine derivative and use thereof

Provided is a compound having a serotonin 5-HTreceptor activating action. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention relates to a serotonin 5-HTreceptor activator containing a compound represented by the formula wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an oxo group wherein the combination of m and n (m,n) is (1,2), (2,1), (2,2), (3,1), (3,2) or (4,1), or a salt thereof or a prodrug thereof, and a fused heterocyclic compound having a serotonin 5-HTreceptor activating action and the like.

Fused heterocyclic compound and use thereof

Growing community of inventors

Osaka, Japan

Tomokazu Kusumoto